Misumi Americas makes US manufacturing strategic priority, the celebrity brand ambassador rise in pharma, AI in the hospital pharmacy, and more.

Wet AMD is an eye disorder characterised by leaky vessels in the retina causing vision loss. Credit: PeopleImages/Shutterstock.com. Following years of regulatory setbacks that saw multiple rejections, ...

The adult epilepsy market across the 7MM is poised to grow at a CAGR of 4.4% from $11.4bn in 2025 to $17.8bn in 2035.

Sanofi is discontinuing amlitelimab’s development in AD, but the Phase II study in celiac disease will continue. Credit: Kwangmoozaa / Shutterstock.com. Sanofi has chosen not to file for approval or ...

BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.

Lundbeck has secured fast track designation from the US FDA for its investigational treatment, Lu AH69593, to treat narcolepsy.

GSK's newly approved ROS1-positive NSCLC drug, Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.

Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.

Evogene and ELEO have entered into a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the PCSK9 pathway for hyperlipidemia and cardiovascular ...